JAZZ - Jazz Pharmaceuticals PLC Stock Price, Fair Value and News

108.31USD-1.36 (-1.24%)Market Closed

Market Summary

USD108.31-1.36

Market Closed

-1.24%

JAZZ Stock Price

View Fullscreen

JAZZ RSI Chart

JAZZ Valuation

Market Cap

6.8B

Price/Earnings (Trailing)

16.48

Price/Sales (Trailing)

1.78

EV/EBITDA

15.78

Price/Free Cashflow

6.4

JAZZ Price/Sales (Trailing)

JAZZ Profitability

EBT Margin

7.77%

Return on Equity

11.1%

Return on Assets

3.64%

Free Cashflow Yield

15.62%

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

3.8B

Rev. Growth (Yr)

4.1%

Rev. Growth (Qtr)

4.09%

JAZZ Earnings

Earnings (TTM)

414.8M

Earnings Growth (Yr)

139.11%

Earnings Growth (Qtr)

-35.87%

Breaking Down JAZZ Revenue

Last 7 days

0.7%

Last 30 days

-10.0%

Last 90 days

-10.9%

Trailing 12 Months

-24.1%

How does JAZZ drawdown profile look like?

JAZZ Financial Health

Current Ratio

2.24

Debt/Equity

1.37

Debt/Cashflow

0.21

JAZZ Investor Care

Buy Backs (1Y)

1.56%

Diluted EPS (TTM)

6.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.7B	3.8B	3.8B	3.8B
2022	3.3B	3.5B	3.6B	3.7B
2021	2.4B	2.6B	2.9B	3.1B
2020	2.2B	2.2B	2.3B	2.4B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.7B	1.8B	1.9B	1.9B
2017	1.5B	1.5B	1.6B	1.6B
2016	1.4B	1.4B	1.4B	1.5B
2015	1.2B	1.3B	1.3B	1.3B
2014	923.1M	1.0B	1.1B	1.2B
2013	679.7M	763.7M	820.4M	872.4M
2012	323.9M	383.6M	485.8M	586.0M
2011	272.3M	272.3M	272.3M	272.3M
2010	164.4M	200.4M	236.3M	272.3M
2009	0	0	0	128.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Jazz Pharmaceuticals PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	gala renee d	sold (taxes)	-200,005	115	-1,736	president & coo
Mar 07, 2024	carr patricia	sold	-206,821	116	-1,768	svp, chief accounting officer
Mar 06, 2024	carr patricia	sold	-231,628	119	-1,936	svp, chief accounting officer
Mar 05, 2024	patil neena m	sold (taxes)	-403,363	117	-3,432	evp & chief legal officer
Mar 05, 2024	cozadd bruce c	sold (taxes)	-2,636,900	117	-22,436	chairman & ceo
Mar 05, 2024	pearce samantha	sold (taxes)	-290,769	117	-2,474	svp, head of europe & internat
Mar 05, 2024	iannone robert	sold (taxes)	-504,674	117	-4,294	evp, global head of r&d
Mar 05, 2024	gala renee d	sold (taxes)	-425,694	117	-3,622	president & coo
Mar 01, 2024	carr patricia	acquired	-	-	2,987	svp, chief accounting officer
Mar 01, 2024	kennedy patrick	acquired	-	-	1,423	-

Which funds bought or sold JAZZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Tennessee Valley Asset Management Partners	sold off	-100	-1,353	-	-%
Apr 23, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	unchanged	-	-34,000	1,553,000	0.06%
Apr 23, 2024	Venturi Wealth Management, LLC	new	-	14,210	14,210	-%
Apr 23, 2024	Gradient Investments LLC	unchanged	-	-15.00	723	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	80.00	7,466	-%
Apr 23, 2024	Louisiana State Employees Retirement System	added	2.26	2,502	2,179,600	0.04%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	-10.00	482	-%
Apr 23, 2024	REGIONS FINANCIAL CORP	reduced	-3.76	-16,069	262,034	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	unchanged	-	328	328	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-8.67	-533,000	4,501,000	0.04%

Are Funds Buying or Selling JAZZ?

Are funds buying JAZZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JAZZ

No. of Funds

Unveiling Jazz Pharmaceuticals PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.11%	6,363,748	SC 13G/A
Jan 24, 2024	blackrock inc.	11.2%	7,055,747	SC 13G/A
Sep 11, 2023	vanguard group inc	10.26%	6,479,474	SC 13G/A
Feb 09, 2023	vanguard group inc	9.61%	6,050,625	SC 13G/A
Jan 26, 2023	blackrock inc.	10.6%	6,652,382	SC 13G/A
Jan 20, 2023	blackrock inc.	10.6%	6,652,382	SC 13G
Jan 05, 2023	jpmorgan chase & co	4.6%	2,924,604	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jan 28, 2022	blackrock inc.	10.5%	6,450,368	SC 13G/A
Jan 24, 2022	jpmorgan chase & co	5.2%	3,248,156	SC 13G

Recent SEC filings of Jazz Pharmaceuticals PLC

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	3	Insider Trading

Peers (Alternatives to Jazz Pharmaceuticals PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Jazz Pharmaceuticals PLC News

Latest updates

Jazz Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	4.1%	1,012	972	957	893	972	941	933	814	897	838	752	608	666	601	562	535	582	538	534	508	476
Costs and Expenses	11.2%	889	800	800	767	1,236	916	847	726	847	810	821	445	492	405	364	724	520	405	330	374	291
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	291
S&GA Expenses	28.5%	396	308	341	298	383	358	366	309	398	364	429	261	247	207	191	208	214	179	176	168	162
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.00	80.00	62.00	60.00	57.00
EBITDA Margin	-	0.17*	-	0.01*	-0.01*	-0.02*	0.03*	0.02*	-0.02*	0.02*	0.05*	0.14*	0.28*	0.14*	-	-	-	-	-	-	-	-
Income Taxes	29.9%	-33.10	-47.20	-24.32	-15.30	-100	-43.00	-16.11	1.00	-12.46	-18.06	229	18.00	11.00	19.00	55.00	-51.29	-34.53	11.00	-78.65	29.00	5.00
Earnings Before Taxes	-38.2%	62.00	100	82.00	55.00	-339	-60.13	21.00	6.00	-44.83	-67.63	-136	136	145	168	171	-209	41.00	114	184	115	165
EBT Margin	384.6%	0.08*	-0.03*	-0.07*	-0.09*	-0.10*	-0.02*	-0.02*	-0.07*	-0.04*	0.03*	0.12*	0.25*	-	-	-	-	-	-	-	-	-
Net Income	-35.9%	94.00	147	104	69.00	-240	-19.65	35.00	2.00	-35.35	-52.83	-363	122	133	148	115	-157	74.00	102	262	85.00	159
Net Income Margin	413.4%	0.11*	0.02*	-0.02*	-0.04*	-0.06*	-0.01*	-0.01*	-0.14*	-0.11*	-0.06*	0.02*	0.21*	-	-	-	-	-	-	-	-	-
Free Cashflow	-48.1%	157	303	291	317	333	423	291	197	168	266	35.00	283	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.7%	11,393	11,204	11,261	11,047	10,835	10,385	11,200	11,769	12,299	12,478	13,213	6,756	6,536	6,292	6,067	5,215	5,539	5,528	5,489	5,280	5,203
Current Assets	5.8%	3,435	3,246	3,010	2,785	2,606	2,572	2,591	2,501	2,611	2,628	2,954	3,167	2,840	2,556	2,302	1,518	1,630	1,521	1,370	1,306	1,234
Cash Equivalents	12.8%	1,506	1,336	1,282	1,168	881	839	711	491	591	672	891	2,098	1,058	742	786	702	637	795	638	547	310
Inventory	-2.4%	597	612	657	675	714	728	862	985	1,073	1,138	1,251	115	95.00	91.00	93.00	86.00	79.00	71.00	69.00	61.00	53.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	124	128	128	128	130	132	129	127	113	200
Goodwill	2.8%	1,753	1,705	1,743	1,723	1,693	1,593	1,688	1,782	1,828	1,850	1,888	938	958	937	918	909	920	907	925	920	928
Current Liabilities	-2.3%	1,537	1,573	945	909	933	813	705	737	809	735	881	752	654	642	410	396	364	390	369	414	345
Long Term Debt	-0.1%	5,108	5,111	5,687	5,690	5,693	5,696	5,990	5,993	6,019	6,247	6,489	1,853	1,849	1,844	2,070	1,577	1,574	1,571	1,568	1,565	1,563
LT Debt, Current	0.1%	605	605	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	249	249	246	244	33.00	33.00	33.00	33.00	33.00	33.00	33.00
LT Debt, Non Current	-0.1%	5,108	5,111	5,687	5,690	5,693	5,696	5,990	5,993	6,019	6,247	6,489	1,853	1,849	1,844	2,070	1,577	1,574	1,571	1,568	1,565	1,563
Shareholder's Equity	7.1%	3,737	3,489	3,526	3,335	3,086	2,745	3,201	3,608	3,965	3,938	4,131	3,798	3,660	3,377	3,142	2,809	3,111	3,054	2,983	2,730	2,757
Retained Earnings	-0.6%	879	884	812	803	734	974	994	959	830	866	918	1,282	1,160	1,026	878	771	1,068	1,104	1,022	820	841
Additional Paid-In Capital	1.6%	3,700	3,640	3,580	3,512	3,477	3,388	3,312	3,239	3,535	3,470	3,403	2,695	2,634	2,538	2,499	2,294	2,266	2,209	2,171	2,131	2,114
Shares Outstanding	-2.0%	62.00	64.00	64.00	63.00	63.00	63.00	62.00	62.00	60.00	59.00	59.00	56.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	7,660	-	-	-	9,527	-	-	-	10,591	-	-	-	5,958	-	-	-	7,870	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-45.5%	167,339	307,195	296,765	320,708	341,971	417,991	303,036	208,979	177,755	274,060	41,695	284,997	186,271	257,889	182,519	272,969	87,798	337,503	148,847	202,253	218,096
Share Based Compensation	-5.7%	52,941	56,115	61,433	56,352	61,558	56,681	53,687	50,070	53,119	53,239	48,163	34,485	31,384	30,356	30,604	28,654	25,937	28,785	28,289	27,552	26,723
Cashflow From Investing	158.4%	101,798	-174,299	-85,739	-4,822	-324,378	4,602	-89,162	-37,292	-10,092	-26,813	-5,912,370	737,132	73,219	-279,644	-741,165	-60,080	-159,053	-159,661	-2,638	166,052	39,992
Cashflow From Financing	-27.8%	-100,306	-78,493	-96,667	-29,788	19,596	-289,053	10,777	-270,811	-246,609	-465,181	4,664,036	18,276	55,878	-22,656	642,534	-147,683	-87,780	-19,463	-56,153	-130,349	-446,456
Buy Backs	34.2%	99,795	74,371	95,594	-	-	-	54.00	-	-	-	-	-	-	-	7,484	139,053	110,335	19,997	59,869	111,249	446,657

JAZZ Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 3,834,204	$ 3,659,374	$ 3,094,238
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	435,577	540,517	440,760
Selling, general and administrative	1,343,105	1,416,967	1,451,683
Research and development	849,658	590,453	505,748
Intangible asset amortization	608,284	599,169	525,769
Acquired in-process research and development	19,000	444,148	0
Intangible asset impairment charge	0	133,648	0
Total operating expenses	3,255,624	3,724,902	2,923,960
Income (loss) from operations	578,580	(65,528)	170,278
Interest expense, net	(289,438)	(288,242)	(278,766)
Foreign exchange gain (loss)	8,787	(19,014)	(4,350)
Income (loss) before income tax expense (benefit) and equity in loss of investees	297,929	(372,784)	(112,838)
Income tax expense (benefit)	(119,912)	(158,645)	216,116
Equity in loss of investees	3,009	9,921	714
Net income (loss)	$ 414,832	$ (224,060)	$ (329,668)
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ 6.55	$ (3.58)	$ (5.52)
Diluted (in dollars per share)	$ 6.10	$ (3.58)	$ (5.52)
Weighted-average ordinary shares used in per share calculations - basic (in shares)	63,291	62,539	59,694
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	72,066	62,539	59,694
Product sales, net
Revenues:
Total revenues	$ 3,736,943	$ 3,641,429	$ 3,079,001
Royalties and contract revenues
Revenues:
Total revenues	$ 97,261	$ 17,945	$ 15,237

JAZZ Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,506,310	$ 881,482
Investments	120,000	0
Accounts receivable, net of allowances of $21,136 and $17,843 at December 31, 2023 and 2022, respectively	705,794	651,493
Inventories	597,039	714,061
Prepaid expenses	185,476	91,912
Other current assets	320,809	267,192
Total current assets	3,435,428	2,606,140
Property, plant and equipment, net	169,646	228,050
Operating lease assets	65,340	73,326
Intangible assets, net	5,418,039	5,794,437
Goodwill	1,753,130	1,692,662
Deferred tax assets, net	477,834	376,247
Deferred financing costs	6,478	9,254
Other non-current assets	67,464	55,139
Total assets	11,393,359	10,835,255
Current liabilities:
Accounts payable	102,750	90,758
Accrued liabilities	793,914	803,255
Current portion of long-term debt	604,954	31,000
Income taxes payable	35,074	7,717
Deferred revenue	0	463
Total current liabilities	1,536,692	933,193
Long-term debt, less current portion	5,107,988	5,693,341
Operating lease liabilities, less current portion	59,225	71,838
Deferred tax liabilities, net	847,706	944,337
Other non-current liabilities	104,751	106,812
Commitments and contingencies (Note 14)
Shareholders’ equity:
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 62,255 and 63,214 shares issued and outstanding at December 31, 2023 and 2022, respectively	6	6
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2023 and 2022	55	55
Capital redemption reserve	473	472
Additional paid-in capital	3,699,954	3,477,124
Accumulated other comprehensive loss	(842,147)	(1,125,509)
Retained earnings	878,656	733,586
Total shareholders’ equity	3,736,997	3,085,734
Total liabilities and shareholders’ equity	$ 11,393,359	$ 10,835,255

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

CEO	Mr. Bruce C. Cozadd
WEBSITE	jazzpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	2800

Jazz Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Jazz Pharmaceuticals PLC? What does JAZZ stand for in stocks?

JAZZ is the stock ticker symbol of Jazz Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jazz Pharmaceuticals PLC (JAZZ)?

As of Tue Apr 23 2024, market cap of Jazz Pharmaceuticals PLC is 6.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers. The fair value of Jazz Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jazz Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JAZZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jazz Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether JAZZ is over valued or under valued. Whether Jazz Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Jazz Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAZZ.

What is Jazz Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, JAZZ's PE ratio (Price to Earnings) is 16.48 and Price to Sales (PS) ratio is 1.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAZZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Jazz Pharmaceuticals PLC's stock?

In the past 10 years, Jazz Pharmaceuticals PLC has provided -0.02 (multiply by 100 for percentage) rate of return.